Skip to main content

Table 1 Clinical characteristics in the four subtypes

From: Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors

Variable All tumors TC AC LCNEC SCLC NA
159 (100.0) 35 (100.0) 2 (100.0) 28 (100.0) 94 (100.0)
Age
 < =59.5 78 (49.1) 25 (71.4) 2 (100.0) 12 (42.9) 39 (41.5)  
 > 59.5 81 (50.9) 10 (28.6) 0 (0.0) 16 (57.1) 55 (58.5)  
Gender
 Male 109 (68.6) 17 (48.6) 0 (0.0) 23 (82.1) 69 (73.4)  
 Female 50 (31.4) 18 (51.4) 2 (100.0) 5 (17.9) 25 (27.6)  
Necrosis
 No 85 (53.5) 35 (100.0) 0 (0.0) 9 (32.1) 41 (43.6)  
 Yes 74 (46.5) 0 (0.0) 2 (100.0) 19 (67.9) 53 (56.4)  
Vascular invasion
 No 129 (81.1) 34 (97.1) 1 (50.0) 22 (78.6) 72 (76.6)  
 Yes 30 (18.9) 1 (2.9) 1 (50.0) 6 (21.4) 22 (23.4)  
Preoperative therapy
 No 150 (94.3) 35 (100.0) 2 (100.0) 27 (96.4) 86 (91.5)  
 Yes 9 (5.7) 0 (0.0) 0 (0.0) 1 (3.6) 8 (8.5)  
First location
 Lung 131 (82.4) 35 (100.0) 2 (100.0) 28 (100.0) 66 (70.2)  
 Lymph Node 28 (17.6) 0 (0.0) 0 (0.0) 0 (0.0) 28 (29.8)  
Lymph Node Metastasis       13 (8.2)
 No 83 (52.2) 32 (97.0) 1 (50.0) 14 (60.9) 36 (40.9)  
 Yes 63 (47.8) 1 (3.0) 1 (50.0) 9 (39.1) 52 (59.1)  
Clinical Staging       15 (9.4)
 I 70 (48.6) 30 (90.9) 1 (50.0) 10 (43.5) 29 (33.7)  
 II 27 (18.8) 2 (6.1) 0 (0.0) 9 (39.1) 16 (18.6)  
 III 47 (32.6) 1 (3.0) 1 (50.0) 4 (17.4) 41 (47.7)  
Patterns of PD-L1
 Tumorpos stromaneg 9 (5.7) 3 (8.6) 0 (0.0) 5 (17.8) 1 (1.1)  
 Stromapostumorneg 46 (28.9) 0 (0.0) 0 (0.0) 12 (42.9) 34 (36.2)  
 Tumor and stromapos 17 (10.7) 0 (0.0) 0 (0.0) 4 (14.3) 13 (13.8)  
 Tumor and stromaneg 87 (54.7) 32 (91.4) 2 (100.0) 7 (25.0) 46 (48.9)  
CD8 density/mm2 in stroma
  ≤ 264.6/mm2 80 (50.3) 23 (65.7) 0 (0.0) 7 (25.0) 50 (53.2)  
  > 264.6/mm2 79 (49.7) 12 (34.3) 2 (100.0) 21 (75.0) 44 (46.8)  
  1. Abbreviation: NA not available